Silo Pharma advances PTSD drug SPC-15

Summary

Silo Pharma Inc. is advancing its main asset SPC-15 for treating PTSD. The company expects preclinical data supporting its IND within 90 days and plans to submit by the end of 2025. If FDA approval is granted, Phase I clinical trials could start by the end of 2026. Silo Pharma is using the FDA’s 505(b)(2) pathway to expedite the process, addressing a significant gap in PTSD treatment options since no new drugs have been approved in nearly 25 years.Reuters

Impact Analysis

First-order effects include Silo Pharma’s potential growth prospects due to SPC-15, given the significant unmet need in PTSD treatment. Successfully navigating FDA approval could lead to early commercialization advantages and a boost in investor confidence. Risks involve regulatory hurdles, time delays, and the company’s current non-compliance with Nasdaq’s minimum bid requirements.Reuters+ 2 Second-order effects could impact other companies in the pharmaceutical industry, especially those focusing on neurological disorders, due to increased competition or collaboration opportunities. Silo Pharma’s recent joint venture with WuXi AppTec on an obesity drug demonstrates strategic diversification, which may mitigate risks associated with SPC-15’s regulatory challenges.StockTitan Investment opportunities might include options strategies focused on regulatory outcome timelines and joint venture success.